Samuel F. Chang

Samuel F. Chang

Auto-generated profile, based on publicly available information

Samuel F. Chang

University of Alabama at Birmingham

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BPBethany C. Prudner
Bethany C. Prudner
RRRicha Rathore
Richa Rathore
ARAnthony M. Robinson
Anthony M. Robinson
AGAbigail Godec
Abigail Godec
SCSamuel F. Chang
Samuel F. Chang
Brian Van TineBrian Van Tine
Brian Van Tine
Purpose: The response to acute and long-term arginine starvation results in a conditional adaptive metabolic reprogramming that can be harnessed for therapeutic opportunities in ASS1-negative tumors. Here, we investigate the underlying biology of priming ASS1− tumors with arginine deiminase (ADI-PEG20) before treatment with gemcitabine (GEM) and docetaxel (DTX) in sarcoma, pancreatic cancer, and melanoma cell lines. Experimental Design: ASS1− tumor cell lines were treated to create LTAT (long-term ADI treated) cell lines (ASS1+) and used for drug combination studies. Protein expression of ASS1, dCK, RRM2, E2F1, c-MYC, and hENT1 was measured. c-MYC activity was determined, live-cell immunofluorescent studies for hENT1, uptake assays of FITC-cytosine probe, and rescue studies with a c-MYC inhibitor were all determined in the presence or absence of the ADI-PEG20:GEM:DTX. Results: In examining modulations within the pyrimidine pathway, we identified that the addition of DTX to cells treated with ADI-PEG20 resulted in translocation of stabilized c-Myc to the nucleus. This resulted in an increase of hENT1 cell-surface expression and rendered the cells susceptible to GEM. In vivo studies demonstrate that the combination of ADI-PEG20:GEM:DTX was optimal for tumor growth inhibition, providing the preclinical mechanism and justification for the ongoing clinical trial of ADI-PEG20, GEM, and DTX in sarcoma. Conclusions: The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression. This finding is applicable to ASS1-deficient cancers that are currently treated with GEM.

3 October 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
CHChae‐Myeong Ha
Chae‐Myeong Ha
SBSayan Bakshi
Sayan Bakshi
MBManoja K. Brahma
Manoja K. Brahma
LPLuke A. Potter
Luke A. Potter
SCSamuel F. Chang
Samuel F. Chang
AWAdam R. Wende
Adam R. Wende
Background: Lifestyle and metabolic diseases influence the severity and pathogenesis of cardiovascular disease through numerous mechanisms, including regulation via posttranslational modifications. A specific posttranslational modification, the addition of O ‐linked β‐ N acetylglucosamine ( O ‐GlcNAcylation), has been implicated in molecular mechanisms of both physiological and pathologic adaptations. The current study aimed to test the hypothesis that in cardiomyocytes, sustained protein O ‐GlcNAcylation contributes to cardiac adaptations, and its progression to pathophysiology. Methods and Results: Using a naturally occurring dominant‐negative O ‐GlcNAcase (dnOGA) inducible cardiomyocyte‐specific overexpression transgenic mouse model, we induced dnOGA in 8‐ to 10‐week‐old mouse hearts. We examined the effects of 2‐week and 24‐week dnOGA overexpression, which progressed to a 1.8‐fold increase in protein O‐ GlcNAcylation. Two‐week increases in protein O ‐GlcNAc levels did not alter heart weight or function; however, 24‐week increases in protein O ‐GlcNAcylation led to cardiac hypertrophy, mitochondrial dysfunction, fibrosis, and diastolic dysfunction. Interestingly, systolic function was maintained in 24‐week dnOGA overexpression, despite several changes in gene expression associated with cardiovascular disease. Specifically, mRNA‐sequencing analysis revealed several gene signatures, including reduction of mitochondrial oxidative phosphorylation, fatty acid, and glucose metabolism pathways, and antioxidant response pathways after 24‐week dnOGA overexpression. Conclusions: This study indicates that moderate increases in cardiomyocyte protein O ‐GlcNAcylation leads to a differential response with an initial reduction of metabolic pathways (2‐week), which leads to cardiac remodeling (24‐week). Moreover, the mouse model showed evidence of diastolic dysfunction consistent with a heart failure with preserved ejection fraction. These findings provide insight into the adaptive versus maladaptive responses to increased O‐ GlcNAcylation in heart.

6 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SCSamuel F. Chang
Samuel F. Chang
CHChae‐Myeong Ha
Chae‐Myeong Ha
MBManoja K. Brahma
Manoja K. Brahma
LPLuke A. Potter
Luke A. Potter
MRMahima S. Reddy
Mahima S. Reddy
AWAdam R. Wende
Adam R. Wende
Background: The observation that patients with diabetes always under tight‐glycemic control consistently show better cardiovascular disease outcomes compared with patients who transition to tight‐glycemic control after prior conventional glycemic control led to the concept of metabolic memory. Mechanisms such as epigenetics possibly mediate the lasting metabolic memory effects, without a known mechanism. Increased cardiac protein posttranslational O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) modification is implicated in cardiac remodeling observed in diabetes, and our previous work shows that chronically elevated cardiomyocyte O‐GlcNAc causes adverse cardiac changes. We hypothesized that transiently increased cardiomyocyte O‐GlcNAcylation leads to exacerbated adverse cardiac remodeling after subsequent pressure‐overload. Methods: Using an inducible cardiomyocyte specific, dominant‐negative O‐GlcNAcase (dnOGAh) mouse and single transgenic littermate controls (Con), we induced O‐GlcNAc levels for 2 weeks (ON), followed by a 2‐week washout (OFF); mice then underwent transverse‐aortic constriction (TAC) or Sham surgery followed by comprehensive physiological and molecular assessments. Results: We observed the expected cardiac remodeling in TAC groups, including decreased cardiac function, and increased hypertrophy and fibrosis. Moreover, these pathologic measures were exacerbated in the ON/OFF‐TAC versus Con‐TAC mice; additionally, transcriptomic analysis of left ventricle tissue from each experimental group showed pathways which supported our fibrosis, hypertrophy and functional results of exacerbated cardiac remodeling, and revealed potential novel molecular pathways underlying this pathologic remodeling. Conclusions: We observed exacerbated cardiac pathology between ON/OFF‐TAC versus Con‐TAC groups supporting the concept of “O‐GlcNAc memory” as a component of metabolic memory. Moreover, transcriptomic analysis provides insight into potential molecular pathways underpinning this metabolic/O‐GlcNAc memory such as Ccn2 /CTGF‐driven fibrosis, and/or Nox4 ‐driven oxidative stress.

14 June 2024 in Medical Science Educator
Verified
Journal Article
Closed access
PDF file
SGSam E. Gary
Sam E. Gary
SCSamuel F. Chang
Samuel F. Chang
CQColin Quinn
Colin Quinn
JBJames Baños
James Baños
BHBrook Hubner
Brook Hubner

4 March 2026 in Epigenetics
Verified
Journal Article
Open access
SBSayan Bakshi
Sayan Bakshi
SCSamuel F. Chang
Samuel F. Chang
LPLuke A. Potter
Luke A. Potter
ZSZhihuan Sun
Zhihuan Sun
CHChae-Myeong Ha
Chae-Myeong Ha
AWAdam R. Wende
Adam R. Wende
Clinically prior hyperglycemia may lead to long-lasting adverse cardiovascular effects, a process referred to as 'glycemic memory.' Epigenetic modifications, specifically DNA methylation changes, may play a key role in this phenomenon. This study investigated if prior high glucose delivery to cardiomyocytes, led to worsened cardiovascular effects upon pressure overload and to ascertain the gene expression and corresponding DNA methylation signatures linked to glycemic memory. Using inducible and cardiomyocyte-specific glucose transporter 4 (GLUT4) overexpressing mice. We induced glucose delivery for 2 weeks, then returned to basal uptake for 2 weeks, followed by sham or transverse aortic constriction (TAC) surgery as a secondary stress. Mice were followed for an additional 8 weeks and assessed for contractile function, cellular remodeling, and molecular changes. TAC led to an exacerbated hypertrophic response and cardiac dysfunction in the transgenic mice. Subsequent analysis identified molecular changes akin to heart failure, worsened cardiac fibrosis, and oxidative stress. Using bulk RNA-sequencing and reduced representation bisulfite sequencing, we discovered differential gene expression and DNA methylation signatures that persisted even after cellular glucose levels reverted to normal. Significant changes across both expression and methylation-identified enriched pathways related to adverse cardiac events, supporting a glycemic memory response. Glycemic memory led to cardiac structural and functional exacerbation, mimicking heart failure, when subjected to a secondary stress. Our data identified transcriptome, and preliminary DNA methylome changes which may potentially be molecular signatures of future therapeutic targets associated with this heart failure susceptibility resulting from enhanced glucose delivery.

31 March 2023
Verified
Other
Open access
BPBethany C. Prudner
Bethany C. Prudner
RRRicha Rathore
Richa Rathore
ARAnthony M. Robinson
Anthony M. Robinson
AGAbigail Godec
Abigail Godec
SCSamuel F. Chang
Samuel F. Chang
Brian Van TineBrian Van Tine
Brian Van Tine
Purpose:The response to acute and long-term arginine starvation results in a conditional adaptive metabolic reprogramming that can be harnessed for therapeutic opportunities in ASS1-negative tumors. Here, we investigate the underlying biology of priming ASS1− tumors with arginine deiminase (ADI-PEG20) before treatment with gemcitabine (GEM) and docetaxel (DTX) in sarcoma, pancreatic cancer, and melanoma cell lines.Experimental Design:ASS1− tumor cell lines were treated to create LTAT (long-term ADI treated) cell lines (ASS1+) and used for drug combination studies. Protein expression of ASS1, dCK, RRM2, E2F1, c-MYC, and hENT1 was measured. c-MYC activity was determined, live-cell immunofluorescent studies for hENT1, uptake assays of FITC-cytosine probe, and rescue studies with a c-MYC inhibitor were all determined in the presence or absence of the ADI-PEG20:GEM:DTX.Results:In examining modulations within the pyrimidine pathway, we identified that the addition of DTX to cells treated with ADI-PEG20 resulted in translocation of stabilized c-Myc to the nucleus. This resulted in an increase of hENT1 cell-surface expression and rendered the cells susceptible to GEM. In vivo studies demonstrate that the combination of ADI-PEG20:GEM:DTX was optimal for tumor growth inhibition, providing the preclinical mechanism and justification for the ongoing clinical trial of ADI-PEG20, GEM, and DTX in sarcoma.Conclusions:The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression. This finding is applicable to ASS1-deficient cancers that are currently treated with GEM.